12/22/2025 CIMERLI® (ranibizumab-eqrn) Available at 90% Discount to LUCENTIS® (ranibizumab injection)
FDA Approved 11/30/2025 EYLEA HD® (aflibercept) Injection Now Approved for A New Indication - 11/24/25